An accomplished scientific professional with decades of experience in the pharmaceutical industry, Dean Billington brings unrivalled technical expertise to his role as Global Chief Operating Officer for Brains Bioceutical. Established in 2019, Brains Bioceutical is a global manufacturer of naturally-sourced active pharmaceutical ingredients (APIs). Billington is responsible for navigating the complex global regulatory landscape of cannabinoids, providing leadership and guidance on compliance auditing, licensing requirements, clinical trials, product development and site operations. Billington has a proven track record of commercial and business development success with major pharmaceutical companies including Caligor RX Ltd., Bilcare GCS Europe Limited, Fisher Clinical Services and Pharmalytic Limited. He has also provided independent consulting services to a wider range of pharmaceutical companies at various stages of growth, providing expertise on all aspects of the drug development cycle including clinical trials, analytical chemistry and quality assurance. In his previous roles, Billington successfully separated two major pharmaceutical companies into independent organizations, developed a new $35-million dollar pharmaceutical manufacturing and development facility and provided strategic direction to small companies, guiding them through expansions, acquisitions and corporate alliances. Billington is a “qualified person” for clinical trials, with authority from the mHRA to release material for human consumption. He is also a “responsible person”, which means he has the authorization to enable the distribution, storage and processing of pharmaceutical products. As Global Chief Operating Officer for Brains Bioceutical, Billington is eager to explore the potential for cannabinoids in the health and wellness sectors. By taking a patient-centric approach to the research, development and commercialization of cannabinoids, Billington is strategically positioning Brains Bioceutical to be a trailblazer in healthcare innovation across the world. He is responsible for leading the development and production of clinical data to support the use of cannabinoids in the prevention and treatment of major diseases. With aspirations to develop a portfolio of cannabinoids to create and treat a variety of medical diseases, Billington is unlocking the potential for cannabinoid health solutions in early-stage drug development.